Lisa M. McGregor, M.D., Ph.D.Interim Chief, Division Of Pediatric Hematology/Oncology
500 University Drive
Hershey, PA 17033
Email: [email protected]
“Penn State’s commitment to childhood cancer research enables us to provide innovative treatment to all of our pediatric cancer patients.”
2018
2016
2011
2009
2008-2012
2006-2012
1996-2012
Children’s Hospital of Philadelphia
“A Phase 2 Multicenter, Historically-Controlled Study of Drug A Added to Standard Chemotherapy in Pediatric Patients”
Role: Institutional PI
08/15/2012-07/31/2019
Children’s Hospital of Philadelphia/ Sanofi-Aventis Us Inc.
“A Phase 1 Dose Escalation Study of Drug A in Pediatric Patients With Refractory Solid Tumors Including Tumors of the CNS”
Role: Institutional PI
04/29/2013-04/30/2016
Children’s Hospital of Philadelphia/Millennium
“Phase 2 Pilot Trial of Drug A in Combination with Intensive Re-induction Therapy for Children With Relapsed Acute Lymph.”
Role: Institutional PI
07/03/2013-06/30/2016
Children’s Hospital of Philadelphia/Pfizer
“Phase 2 Study of Drug A in Recurr, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Peds and Young Adult Patients”
Role: Institutional PI
07/03/2013-06/30/2017
Memorial Sloan-Kettering
“A Phase II Trial of Drug A, Drug B and Drug C in Patients with Relapsed/Refractory Ewing’s Sarcoma and Beuroblastoma”
10/23/2013-09/30/2018
Children’s Hospital of Philadelphia
“Intergroup Trial for Children of Adolescents with B-Cell NHL or B-Al: Eval of Drug X Efficacy and Safety in High Risk Patients”
08/01/2014-08/31/2019
Children’s Hospital of Philadelphia
“COG Protocol AALL1421 A Dose Confirmation and Pharmacokinetic Study of Drug X Administered as Intravenous (IV) Infusion”
01/20/2015-01/31/2018
Dr. McGregor oversees the clinical enterprise of the division and is the medical director of the Pediatric Hematology/Oncology Clinic and Pediatric Infusion Center. Her clinical interests are focused on children with cancer, especially solid tumors. Dr. McGregor is also committed to improving the quality and safety of the care of patients and participates in several committees within Penn State Children’s Hospital dedicated to this mission.
She continues to participate in research efforts to improve cure rates for children with cancer as the Principal Investigator for the Children’s Oncology Group (COG) at Penn State Children’s Hospital and to develop therapies for children with cancer through her work in the national Pediatric Oncology Experiemental Therapeutics Investigators’ Consortium (POETIC) and the institutional Four Diamonds Experimental Therapeutics Research and Clinical Team (ExTRaCT).
The following are publications of Dr. McGregor’s lab since 2012:
Lam CG, Furman WL, Wang C, Spunt SL, Wu J, Ivy P, Santana VM, McGregor LM. Phase I Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in pediatric patients with refractory solid tumors. J Pediatr Hematol Oncol 37(1):e13-8, 2015.
Federico SM, Allewelt HB, Spunt SL, Hudson MM, Wu J, Billups CA, Jenkins J, Santana VM, Furman WL, McGregor LM. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 37(1): e6-e12, 2015.
Muthusami S, Talker M,, Comito M, McGregor L, Greiner R. Therapy related myelodysplastic syndrome (t-MDS) presenting as recurrent autoimmune systemic vasculitis successfully managed with decitabine. (in submission)
Brennan RC, Furman w, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM. Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 74(6):1191-8, 2014 (epub 2014).
Lam CG, Furman WL, Wang C, Spunt SL, Wu J, Ivy P, Santana VM, McGregor LM. Phase I Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in pediatric patients with refractory solid tumors. J Pediatr Hematol Oncol 37(1):e13-8, 2015 (epub 2014).
Federico SM, Allewelt HB, Spunt SL, Hudson MM, Wu J, Billups CA, Jenkins J, Santana VM, Furman WL, McGregor LM. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 37(1): e6-e12, 2015 (epub 2014).
Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol 32(14): 1445-52, 2014.
Kieran K, Williams MA, McGregor LM, Dome JS, Krasin MJ, Davidoff AM. Repeat nephron-spraing surgery for children with bilateral Wilms tumor. J Pediatr Surg 49(1):149-53,2013.
Pinto EM, Morton C, Rodriguez-Galindo C, McGregor L, Davidoff AM, Mercer K, Debelenko LV, Billups C, Ribeiro RC, Zambetti GP. Establishment and Characterization of the First Pediatric Adrenocortical Carcinoma Xenograft Model Identifies Topotecan as a Potential Chemotherapeutic Agent. Clin Cancer Res. 2013 Mar 18. [Epub ahead of print]
Hartwich JE, Orr WS, Ng CY, Spence Y, McLaughlin JM, Furman WL, McGregor LM,Davidoff AM. Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model. JPediatr Sur,g 48(1):47-55, 2013.
Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, Furman WL, McGregor LM, Hu S, Panetta JC, Turner D, Fofana D, Reddick WE, Leung W, Santana VM. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res, 19(1):236-46, 2013.
Pai Panandiker AS, Beltran C, Billups CA, McGregor LM, Furman WL, Davidoff AM.
Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma. Pediatr Blood Cancer, 60(5):761-5, 2013.
Pinto EM, Ribeiro RC, Li J, Taja-Chayeb L, Carrasco LF, de Lourdes Pena-Torres M, Vidal-Millan S, Maldonado-MTZ H, Duenas-Gonzalez A, McGregor L, Zambetti GP. An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers. Oncogenesis, 2012.
McGregor LM, Stewart CF, Crews KR, Tagen M, Wozniak A, Wu J, McCarville MB, Navid F, Santana VM, Houghton PJ, Furman WL, Rodriguez Galindo C. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer, 58(3):372-9, 2012.
Krasin MJ, Wiese KM, Spunt SL, Hua CH, Daw N, Navid F, Davidoff AM, McGregor L, Merchant TE, Kun LE, McCrarey L, Hoth KA, Yan X, Xiong X. Jaw dysfunction related to pterygoid and masseter muscle dosimetry after radiation therapy in children and young adults with head-and-neck sarcomas. Int J Radiat Oncol Biol Phys, 82(1): 355-60, 2012.
Kieran K, Williams MA, Dome JS, McGregor LM, Krasin MJ, Davidoff AM. Margin status and tumor recurrence after nephron-sparing surgery for bilateral Wilms tumor. J Pediatr Surg 48(7): 1481-5, 2011.
